Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively

Cancer Research

Volumn 74, Issue 7, 2014, Pages 1913-1923

  Weber, Thomas G ^a   Osl, Franz ^a   Renner, Anja ^a   Pöschinger, Thomas ^a   Galbán, Stefanie ^b   Rehemtulla, Alnawaz ^b   Scheuer, Werner ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEATH RECEPTOR 5 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CANCER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG PENETRATION; DRUG RETENTION; FEMALE; FLUORESCENCE MICROSCOPY; GLIOBLASTOMA; MOLECULAR IMAGING; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CELL LINE, TUMOR; FEMALE; GLIOMA; MICE; MICE, HAIRLESS; MICROSCOPY, FLUORESCENCE; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84897386457     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3001     Document Type: Article

References (50)

1. Frank RT, Aboody KS, Najbauer J. Strategies for enhancing antibody delivery to the brain. Biochim Biophys Acta 2011;1816:191-8.
2. Grossi PM, Ochiai H, Archer GE, McLendon RE, Zalutsky MR, Friedman AH, et al. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res 2003;9:5514-20.
3. Chamberlain MC. Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability. Expert Rev Neurother 2010;10:547-61.
4. Watts RJ, Dennis MS. Bispecific antibodies for delivery into the brain. Curr Opin Chem Biol 2013;17:393-9.
5. Siegal T. Which drug or drug delivery system can change clinical practice for brain tumor therapy? Neuro Oncol 2013;15: 656-69.
6. Meikle SR, Matthews JC, Brock CS, Wells P, Harte RJ, Cunningham VJ, et al. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemother Pharmacol 1998;42:183-93.
7. Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, et al. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-Arterial administration. Cancer Chemother Pharmacol 1998;42:433-40.
8. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004;10: 3728-36.
9. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2012;107: 359-64.
10. Fukai J, Nishio K, Itakura T, Koizumi F. Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III. Cancer Sci 2008;99:2062-9.
11. Mineo JF, Bordron A, Quintin-Rou-e I, Loisel S, Ster KL, Buh-e V, et al. Recombinant humanised anti-HER2/neu antibody (Herceptin-) induces cellular death of glioblastomas. Br J Cancer 2004;91:1195-9.
12. Bagci-Onder T, Agarwal A, Flusberg D, Wanningen S, Sorger P, Shah K. Real-Time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors. Oncogene 2012; 32:2818-27.
13. WongMLH, Kaye AH, Hovens CM. Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci 2007;14: 301-8.
14. Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain JF, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 2009;20:1596-603.
15. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-17.
16. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 2004;3:430-46.
17. Aprile I, Muti M, Principi M, Bartolini N, Zenoni A, Tazza G, et al. A Magnetic resonance comparative study between enhancement, rCBV and ACD in brain glioblastomas. Radiol Med 2002;104:87-91.
18. Schlageter KE, Molnar P, Lapin GD, Groothuis DR. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 1999;58:312-28.
19. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007; 25:1350-6.
20. Daghighian F, Pentlow KS, Larson SM, Graham MC, DiResta GR, Yeh SD, et al. Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med 1993;20:402-9.
21. HoldhoffM, Supko JG, Gallia GL, Hann CL, Bonekamp D, Ye X, et al. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol 2010;97: 241-5.
22. Friden PM,Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM. Anti-Transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci U S A 1991;88: 4771-5.
23. Neuwelt EA, Barnett PA, Hellstrom KE, Hellstrom I, McCormick CI, Ramsey FL. Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J Nucl Med 1994;35:1831-41.
24. Iqbal U, Trojahn U, Albaghdadi H, Zhang J, O'Connor-McCourt M, Stanimirovic D, et al. Kinetic analysis of novel mono-And multivalent VHH-fragments and their application for molecular imaging of brain tumours. Br J Pharmacol 2010;160:1016-28.
25. Vajkoczy P, Ullrich A, Menger MD. Intravital fluorescence videomicroscopy to study tumor angiogenesis and microcirculation. Neoplasia 2000;2:53-61.
26. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 1994;54:4564-8.
27. Galb-An S, Jeon YH, Bowman BM, Stevenson J, Sebolt KA, Sharkey LM, et al. Imaging proteolytic activity in live cells and animal models. PloS ONE 2013;8:e66248.
28. Weber TG, Poschinger T, Galb-An S, Rehemtulla A, Scheuer W. Noninvasive monitoring of pharmacodynamics and kinetics of a Death Receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin. Neoplasia 2013;15:863-74.
29. Fiveash JB, Gillespie GY, Oliver PG, Zhou T, Belenky ML, Buchsbaum DJ. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. Int J Radiat Oncol Biol Phys 2008;71:507-16.
30. Saito R, Bringas JR, Panner A, Tamas M, Pieper RO, Berger MS, et al. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 2004;64:6858-62.
31. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000;60:847-53.
32. Adams C. DR5 antibodies and uses thereof. WIPO patent US 20070031414 A1. 2006 oct 10.
33. Erturk A, Becker K, Jahrling N, Mauch CP, Hojer CD, Egen JG, et al. Three-dimensional imaging of solvent-cleared organs using 3DISCO. Nat Protoc 2012;7:1983-95.
34. Dobosz M, Ntziachristos V, Scheuer W, Strobel S. Multispectral fluorescence ultramicroscopy: three-dimensional visualization and automatic quantification of tumor morphology, drug penetration, and antiangiogenic treatment response. Neoplasia 2014;16:1-13.
35. Abuqayyas L, Balthasar JP. Investigation of the role of FcgR and FcRn in mAb distribution to the brain. Mol Pharm 2013;10:1505-13.
36. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE. Passage of amyloid b protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 2002; 23:2223-6.
37. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007;18: 23-8.
38. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 2007;67:9463-71.
39. Criscuolo GR, Merrill MJ, Oldfield EH. Characterization of a protein product of human malignant glial tumors that induces microvascular permeability. Adv Neurol 1990;52:469-74.
40. Blasberg RG, Nakagawa H, Bourdon MA, Groothuis DR, Patlak CS, Bigner DD. Regional localization of a glioma-Associated antigen defined bymonoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy. Cancer Res 1987;47:4432-43.
41. Sarin H, Kanevsky AS,WuH, Sousa AA, Wilson CM, Aronova MA, et al. Physiologic upper limit of pore size in the blood-Tumor barrier of malignant solid tumors. J Transl Med 2009;7:51.
42. Qin DX, Zheng R, Tang J, Li JX, Hu YH. Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys 1990;19:1507-10.
43. Tzeng SY, Green JJ. Therapeutic nanomedicine for brain cancer. Ther Deliv 2013;4:687-704.
44. Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol 2011; 13:437-46.
45. Wilhelm I, Moln-Ar J, Fazakas C, Hask-o J, Krizbai IA. Role of the bloodbrain barrier in the formation of brain metastases. Int J Mol Sci 2013;14:1383-411.
46. Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos 2013;41:33-9.
47. Pels H, Schulz H, Schlegel U, Engert A. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 2003;26:351-4.
48. Burvenich IJ, Lee FT, Cartwright GA, O'Keefe GJ, Makris D, Cao D, et al. Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008. Clin Cancer Res 2013;19:5984-93.
49. Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol 2001;114: 168-72.
50. PardridgeWM. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug Chem 2008;19:1327-38.